Clinical Trials
41 trialsPSMAddition
Novartis
PSMACare
Novartis
STARLiT
Case Comprehensive Cancer Center
COCORIVO
Centre Henri Becquerel
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
PREDICT
Alliance for Clinical Trials in Oncology
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
P300
Pathos AI, Inc.
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
UPLIFT
University of California, San Francisco
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
LUTACT
University of California, San Francisco
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
PSMAfore
Novartis
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Bullseye
Radboud University Medical Center
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
VA Office of Research and Development
PROQURE-1
The Netherlands Cancer Institute
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Alliance for Clinical Trials in Oncology
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Blue Earth Therapeutics Ltd
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
CATCH-177
Case Comprehensive Cancer Center
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Excel Diagnostics and Nuclear Oncology Center
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
VISION
Endocyte
LuTectomy
Peter MacCallum Cancer Centre, Australia
LUNAAR
Baptist Health South Florida
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Weill Medical College of Cornell University
Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Radboud University Medical Center